4.7 Review

TRP channels in lower urinary tract dysfunction

期刊

BRITISH JOURNAL OF PHARMACOLOGY
卷 171, 期 10, 页码 2537-2551

出版社

WILEY
DOI: 10.1111/bph.12502

关键词

TRP channel; lower urinary tract; urology

资金

  1. Belgian Federal Government [IUAP P7/13]
  2. Research Foundation - Flanders [G.0825.11]
  3. Research Council of the KU Leuven (PF-TRPLe)
  4. Astellas

向作者/读者索取更多资源

Lower urinary tract dysfunction (LUTd) represents a major healthcare problem. Although it is mostly not lethal, associated social disturbance, medical costs, loss of productivity and especially diminished quality of life should not be underestimated. Although more than 15% of people suffer from a form of LUTd to some extent, pathophysiology often remains obscure. In the past 20 years, transient receptor potential (TRP) channels have become increasingly important in this field of research. These intriguing ion channels are believed to be the main molecular sensors that generate bladder sensation. Therefore, they are intensely pursued as new drug targets for both curative and symptomatic treatment of different forms of LUTd. TRPV1 was the first of its class to be investigated. Actually, even before this channel was cloned, it had already been targeted in the bladder, with clinical trials of intravesical capsaicin instillations. Several other polymodally gated TRP channels, particularly TRPM8, TRPA1 and TRPV4, also appear to play a prominent role in bladder (patho)physiology. With this review, we provide a brief overview of current knowledge on the role of these TRP channels in LUTd and their potential as molecular targets for treatment. Linked ArticlesThis article is part of a themed section on the pharmacology of TRP channels. To view the other articles in this section visit

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Urology & Nephrology

ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer

Gaetan Devos, Lorenzo Tosco, Marcella Baldewijns, Thomas Gevaert, Karolien Goffin, Valentin Petit, Cindy Mai, Annouschka Laenen, Yannic Raskin, Carl Van Haute, Lieven Goeman, Gert De Meerleer, Charlien Berghen, Wout Devlies, Frank Claessens, Hendrik Van Poppel, Wouter Everaerts, Steven Joniau

Summary: In this study, it was demonstrated that the combination of degarelix and apalutamide prior to radical prostatectomy significantly improved tumor response in high-risk prostate cancer patients compared to degarelix alone. These trial results provide a solid hypothesis-generating basis for neoadjuvant phase 3 trials to detect differences in long-term oncological outcomes.

EUROPEAN UROLOGY (2023)

Article Urology & Nephrology

Defining the optimal template of salvage lymph node dissection for unilateral pelvic nodal recurrence of prostate cancer following radical prostatectomy

Henri Van Eecke, Gaetan Devos, Bram Vansevenant, Arthur Vander Stichele, Wout Devlies, Charlien Berghen, Wouter Everaerts, Gert De Meerleer, Steven Joniau

Summary: The study suggests that unilateral pelvic salvage lymph node dissection (sLND) may be sufficient in patients with unilateral pelvic lymph node recurrence on PET/CT imaging.

INTERNATIONAL JOURNAL OF UROLOGY (2023)

Article Radiology, Nuclear Medicine & Medical Imaging

A Drop-in Gamma Probe for Minimally Invasive Sentinel Lymph Node Dissection in Prostate Cancer Preclinical Evaluation and Interim Results From a Multicenter Clinical Trial

Jose M. Abascal Junquera, Nina N. Harke, Jochen C. Walz, Boris Hadaschik, Jim Adshead, Wouter Everaerts, Karolien Goffin, Maarten R. Grootendorst, Francesca Oldfield, Kunal Vyas, Antoni Mestre Fusco, Nuria Juanpere, Sergi Vidal-Sicart, Lluis Fumado

Summary: This study evaluated the performance of a drop-in gamma probe for SLND in PCa patients. The probe successfully detected sentinel lymph nodes in all patients, outperforming the rigid laparoscopic gamma probe. No adverse events or false-negative cases were reported.

CLINICAL NUCLEAR MEDICINE (2023)

Article Pharmacology & Pharmacy

pH-dependent modulation of TRPV1 by modality-selective antagonists

Jan Daniluk, Thomas Voets

Summary: TRPV1 antagonists have pH-dependent effects on channel inhibition, but their modality selectivity is not strict. The antagonistic efficacy of TRPV1 antagonists is limited at acidic pH, which may restrict their analgesic efficacy in injured tissues.

BRITISH JOURNAL OF PHARMACOLOGY (2023)

Article Clinical Neurology

Primidone improves symptoms in TRPM3-linked developmental and epileptic encephalopathy with spike-and-wave activation in sleep

Lena-Luise Becker, Denise Horn, Felix Boschann, Evelien Van Hoeymissen, Thomas Voets, Joris Vriens, Christine Prager, Angela M. Kaindl

Summary: DEE-SWAS is an age-dependent disease that causes cognitive decline. This study reports on two children with DEE-SWAS and developmental delay/regression, who had missense variants in the TRPM3 gene. Treatment with primidone improved their developmental regression, psychomotor development, and eliminated CSWS.

EPILEPSIA (2023)

Article Pharmacology & Pharmacy

Inhibition of TRPM8 by the urinary tract analgesic drug phenazopyridine

Noemie Luyts, Jan Daniluk, Ana Cristina Nogueira Freitas, Bahar Bazeli, Annelies Janssens, Marie Mulier, Wouter Everaerts, Thomas Voets

Summary: In this study, the effect of Phenazopyridine (PAP) on pain-related Transient Receptor Potential (TRP) channels was investigated. The results showed that PAP can rapidly and reversibly inhibit the cold and menthol sensitivity of TRPM8 channels. This suggests that the inhibition of TRPM8 may be the mechanism underlying the analgesic activity of PAP.

EUROPEAN JOURNAL OF PHARMACOLOGY (2023)

Editorial Material Urology & Nephrology

Adjuvant Docetaxel in Nonmetastatic Prostate Cancer: The King Is Dead, Long Live the King!

Thomas Van den Broeck, Steven Joniau, Wouter Everaerts

EUROPEAN UROLOGY (2023)

Review Oncology

Double trouble for prostate cancer: synergistic action of AR blockade and PARPi in non-HRR mutated patients

Alexander Giesen, Loic Baekelandt, Wout Devlies, Gaetan Devos, Herlinde Dumez, Wouter Everaerts, Frank Claessens, Steven Joniau

Summary: This review provides a comprehensive overview of the synergistic effect of maximal androgen receptor (AR) blockade through the combination of an AR signaling inhibitor (ARSI) and a poly-(ADP-ribose)-polymerase (PARP) inhibitor (PARPi) in both homologous recombination repair (HRR)-mutated and HRR-non-mutated prostate cancer (PCa) patients. The inhibition of PARP enhances the effect of ARSI by preventing the repair of single-strand DNA breaks and inducing the accumulation of DNA double-strand breaks. This leads to apoptosis in the HRR-deficient state induced by combining androgen deprivation therapy (ADT) with ARSI.

FRONTIERS IN ONCOLOGY (2023)

Meeting Abstract Urology & Nephrology

NEW TECHNIQUE FOR VIDEO URODYNAMICS IN MICE ALLOWS NEW INSIGHTS INTO THE ROLE OF ION CHANNEL TRPV4 IN THE MURINE LOWER URINARY TRACT

Helene De Bruyn, Noemie Luyts, Thomas Voets, Wouter Everaerts

JOURNAL OF UROLOGY (2022)

Meeting Abstract Urology & Nephrology

INTERIM RESULTS FROM A MULTICENTER CLINICAL TRIAL EVALUATING A DROP-IN GAMMA PROBE FOR SENTINEL LYMPH NODE DISSECTION IN PROSTATE CANCER

Jose Maria Abascal Junquera, Nuria Juanpere, Marta Corcoy, Maria Yolanda Aguilar, Jochen Christoph Walz, Wouter Everaerts, Karolien Goffin, Maarten Ruben Grootendorst, Francesca Oldfield, Antoni Mestre Fusco, Sergi Vidal-Sicart, Lluis Fumado

JOURNAL OF UROLOGY (2022)

Meeting Abstract Urology & Nephrology

Mechanism of action of Phenazopyridine

N. Luyts, H. De Bruyn, T. Voets, W. Everaerts

EUROPEAN UROLOGY (2022)

Meeting Abstract Urology & Nephrology

PEACE V - Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute toxicity of a randomized phase II trial

P. Ost, S. Siva, R. Heikkila, P. Dirix, N. Liefhooghe, F-X Otte, A. Gomez-Iturriaga, W. Everaerts, M. Shelan, A. Conde-Moreno, F. Lopez Campos, A. Papachristofilou, M. Guckenberger, M. Scorsetti, A. Zapatero, A-E Villafranca Iturre, C. Eito, F. Counago, P. Muto, L. Van De Voorde, V Fonteyne, D. Reynders, T. Zilli

EUROPEAN UROLOGY (2022)

Meeting Abstract Oncology

PEACE V - STORM randomized phase II trial for oligorecurrent nodal prostate cancer: acute toxicity

T. Zilli, S. Siva, R. Heikkila, P. Dirix, N. Liefhooghe, F. Otte, A. Gomez-Iturriaga, W. Everaerts, M. Shelan, A. Conde-Moreno, F. Lopez Campos, A. Papachristofilou, M. Guckenberger, M. Scorsetti, A. Zapatero, A. Villafranca Iturre, C. Eito, F. Counago, P. Muto, L. Van De Voorde, V. Fonteyne, D. Moon, K. Thon, C. Mercier, V. Achard, K. Stellamans, E. Goetghebeur, D. Reynders, P. Ost

RADIOTHERAPY AND ONCOLOGY (2022)

Meeting Abstract Oncology

Hematological toxicity in pN1 prostate cancer patients treated with extended field irradiation

C. Berghen, A. Laenen, R. De Roover, D. Dierickx, S. Joniau, K. Rans, W. Crijns, E. Baten, H. Dumez, W. Everaerts, G. De Meerleer

RADIOTHERAPY AND ONCOLOGY (2022)

暂无数据